Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

prnewswire

Oct 20

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center (Presentation # LBA5, Presidential Symposium II) and were simultaneously published in the New England Journal of Medicine (Impact Factor = 78.5).

Continue Reading

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576886479"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576886479\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576886479?lang=en_US&edition=fundamental","thumbnail":"https://mma.prnewswire.com/media/2800040/image_5028780_3258648.jpg?w=300","is_english":true,"pubTime":"2025-10-20 10:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576886479","market":"sh","top_or_hot":-1,"title":"Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM","media":"prnewswire","content":"<html><body><div>\n<div>\n<p> <span>CHENGDU, China</span>, <span>Oct. 20, 2025</span> /PRNewswire/ -- <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)  in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center (Presentation # LBA5, Presidential Symposium II) and were simultaneously published in the <i><a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine</i> (Impact Factor = 78.5).</p>\n<div>\n<span>\nContinue Reading\n                  <br/>\n<i></i>\n</span>\n</div>\n<div>\n<div>\n<div>\n<div>\n</div>\n<div>\n<div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPositive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1055060725\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">prnewswire </p>\n<p class=\"h-time\">2025-10-20 10:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<p> <span>CHENGDU, China</span>, <span>Oct. 20, 2025</span> /PRNewswire/ -- <a href=\"https://laohu8.com/S/002422\">Sichuan Kelun</a>-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)  in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center (Presentation # LBA5, Presidential Symposium II) and were simultaneously published in the <i><a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine</i> (Impact Factor = 78.5).</p>\n<div>\n<span>\nContinue Reading\n                  <br/>\n<i></i>\n</span>\n</div>\n<div>\n<div>\n<div>\n<div>\n</div>\n<div>\n<div>\n<div>\n<div></div>\n</div>\n<div></div>\n<div></div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div>\n<div></div>\n<figure>\n<div>\n<img itemprop=\"contentUrl\" loading=\"lazy\" rel=\"newsImage\" title=\"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\"/>\n<span aria-hidden=\"true\"></span>\n</div>\n<figcaption>\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      </figcaption>\n</figure>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADC.AU","symbol_name":"ACDC Metals Ltd","start_time":0,"source_url":"https://www.prnewswire.com/apac/news-releases/positive-results-from-phase-3-optitrop-lung04-trial-of-sacituzumab-tirumotecan-presented-at-esmo-presidential-symposium-and-simultaneously-published-in-nejm-302588507.html","article_id":"2576886479","we_media_id":"1055060725","thumbnails":["https://mma.prnewswire.com/media/2800040/image_5028780_3258648.jpg?w=300"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576886479","pubTimestamp":1760927760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"prnewswire","introduction":"prnewswire","home_visible":1,"id":"1055060725","head_image":"https://community-static.tradeup.com/news/9abe841f16459a33d7aa52e466330e3c"},"summary":"CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.  announced that at the 2025 European Society for Medical Oncology  Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 -directed antibody-drug conjugate sacituzumab tirumotecan in EGFR-mutated non-small cell lung cancer  following progression on epidermal growth factor receptor-tyrosine kinase inhibitors  was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center  and were simultaneously published in the New England Journal of Medicine .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADC.AU":"ACDC Metals Ltd","BK7095":"多种金属与采矿","ADC":"艾格里房产","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托"},"translate_title":"sacituzumab tirumotecan 3期OptiTROP-Lung04试验的阳性结果在ESMO总统研讨会上发表，并同时发表在NEJM上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"ADC.AU":1},"content_text":"CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the \"Company\") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT)  in EGFR-mutated non-small cell lung cancer (NSCLC) following progression on epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) was presented as an oral report by Professor Li Zhang from Sun Yat-sen University Cancer Center (Presentation # LBA5, Presidential Symposium II) and were simultaneously published in the New England Journal of Medicine (Impact Factor = 78.5).\n\n\nContinue Reading\n                  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)\r\n      \n\n\n\n\n\n\n\n\n\r\n        (PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}